Page 223 - Read Online
P. 223
Page 8 of 9 Tang et al. Hepatoma Res 2019;5:19 I http://dx.doi.org/10.20517/2394-5079.2019.07
Ethical approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Copyright
© The Author(s) 2019.
REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.
2. Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, et al. Hepatocellular carcinoma. Nat Rev Dis Primers 2016;2:16018.
3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
4. Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology
2015;61:184-90.
5. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with
advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med
2008;359:378-90.
7. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol
2006;6:715-27.
8. Chew V, Lai L, Pan L, Lim CJ, Li J, et al. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-
dimensional proteomic and transcriptomic analyses. Proc Natl Acad Sci USA. 2017;114:E5900-E09.
9. Conway JR, Kofman E, Mo SS, Elmarakeby H, Van Allen E. Genomics of response to immune checkpoint therapies for cancer:
implications for precision medicine. Genome Med 2018;10:93.
10. Ruggeri RM, Campenni A, Giuffrida G, Trimboli P, Giovanella L, et al. Endocrine and metabolic adverse effects of immune
checkpoint inhibitors: an overview (what endocrinologists should know). J Endocrinol Invest 2018.
11. Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, et al. Overall survival with combined nivolumab and ipilimumab
in advanced melanoma. N Engl J Med 2017;377:1345-56.
12. Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, et al. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced
Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and
CheckMate 057). J Clin Oncol 2017;35:3924-33.
13. Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, et al. Nivolumab plus ipilimumab versus sunitinib in advanced
renal-cell carcinoma. N Engl J Med 2018;378:1277-90.
14. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the
PRISMA statement. Ann Intern Med 2009;151:264-9, W64.
15. Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, et al. A clinical trial of CTLA-4 blockade with tremelimumab
in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013;59:81-8.
16. Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, et al. Tremelimumab in combination with ablation in
patients with advanced hepatocellular carcinoma. J Hepatol 2017;66:545-51.
17. Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma
previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 2018;19:940-52.
18. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, et al. Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492-502.
19. Feng D, Hui X, Shi-Chun L, Yan-Hua B, Li C, et al. Initial experience of anti-PD1 therapy with nivolumab in advanced hepatocellular
carcinoma. Oncotarget 2017;8:96649-55.
20. Wainberg ZA, Segal NH, Jaeger D, Lee K-H, Marshall J, et al. Safety and clinical activity of durvalumab monotherapy in patients
with hepatocellular carcinoma (HCC). Journal of Clinical Oncology 2017;35:4071.
21. Kelley RK, Abou-Alfa GK, Bendell JC, Kim T-Y, Borad MJ, et al. Phase I/II study of durvalumab and tremelimumab in patients with
unresectable hepatocellular carcinoma (HCC): phase I safety and efficacy analyses. Journal of Clinical Oncology 2017;35:4073.
22. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359:1350-5.
23. Clark DP. Biomarkers for immune checkpoint inhibitors: the importance of tumor topography and the challenges to cytopathology.
Cancer Cytopathol 2018;126:11-9.
24. Oxnard GR, Wilcox KH, Gonen M, Polotsky M, Hirsch BR, et al. Response rate as a regulatory end point in single-arm studies of
advanced solid tumors. JAMA Oncol 2016;2:772-9.
25. Xu F, Jin T, Zhu Y, Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res 2018;37:110.
26. Planchard D, Yokoi T, McCleod MJ, Fischer JR, Kim YC, et al. A phase III study of durvalumab (MEDI4736) with or without
tremelimumab for previously treated patients with advanced NSCLC: rationale and protocol design of the ARCTIC study. Clin Lung
Cancer 2016;17:232-6.e1.